ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "comparative effectiveness"

  • Abstract Number: 1306 • ACR Convergence 2024

    A Comparative Analysis of ChatGPT-4, Microsoft’s Bing and Google’s Bard at Answering Rheumatology Clinical Questions

    Pitchaporn Yingchoncharoen1, Nattanicha Chaisrimaneepan2, watsachon Pangkanon1 and Jerapas Thongpiya1, 1Texas Tech Health Sciences Center, Lubbock, TX, 2Texas Tech University Health Sciences Center, Lubbock, TX

    Background/Purpose: The role of artificial intelligence (AI) is rapidly expanding in medical fields, with an increased frequency of use by both patients and providers. There…
  • Abstract Number: 1526 • ACR Convergence 2023

    Evusheld Efficacy and Safety in Autoimmune Rheumatic Diseases (AIRD) Treated by B Cell Depeting Therapy or Autologous Stem Cell Transplantation: A Prospective Observational Study

    Lisa Kaly1, mark Volevich1, shiri keret2, Abid Awisat3, Aniela Shouval1, Itzhak Rosner4, Michel Rozenbaum1, Nina Boulman1 and Doron Rimar1, 1Bnai Zion Medical Center, Haifa, Israel, 2Bnai Zion, Atlit, Israel, 3Bney-Zion Medical Center, Baqa Elgharbiya, Israel, 4Bnai Zion Medical Center/Technion, Haifa, Israel

    Background/Purpose: B cell depleting therapy (rituximab) and Autologous Hematopoietic Stem Cell transplantation (AHSCT) result in impaired ability to mount a humoral immune response. Evusheld (tixagevimab…
  • Abstract Number: 1551 • ACR Convergence 2023

    Measurement of Sinonasal Disease Activity in Granulomatosis with Polyangiitis

    Roger Yang1, Ellen Romich2, Shubhasree Banerjee3, Naomi Amudala3, Peter Merkel3, Joshua Baker3 and Rennie Rhee3, 1University of Pennsylvania, Montréal, QC, Canada, 2Hospital of the University of Pennsylvania, Media, PA, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: In granulomatosis with polyangiitis (GPA), sinonasal inflammation can be severe and significantly impact quality of life. Little is known about the most effective local…
  • Abstract Number: 1579 • ACR Convergence 2023

    Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus

    April Jorge1, Baijun Zhou1, Natalie McCormick1, Chio Yokose1, Yuqing Zhang2 and Hyon K. Choi3, 1Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital and Harvard Medical School, Lexington, MA

    Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2) have benefits on kidney and cardiovascular (CV) outcomes that are largely independent of glycemic control. These benefits have been demonstrated…
  • Abstract Number: 1673 • ACR Convergence 2023

    Immunomodulatory Treatment and Autoimmune Patient Responses to COVID-19 Booster Shots: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study

    Amy S. Mudano1, Gary Cutter2, Ted R Mikuls3, Geoffrey Thiele4, Emily Holladay2, Kevin Withrop5, Mark Law4, Bart Hamilton4, Monique Bastidas6, Michael Zikry6, Kelly Chun6, Michael George7 and Jeffrey Curtis2, 1Illumination Health, Hoover, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, 6Labcorp, Calabasas, CA, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Given an increased risk of COVID-19 in patients with autoimmune conditions, we must better understand the immunogenicity and safety of SARS-CoV-2 vaccines in people…
  • Abstract Number: 2008 • ACR Convergence 2023

    Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

    Jeffrey Curtis1, Tarun Arora2, Ye Liu1, Tzu-Chieh Lin3, Leslie Spangler3, Vanessa C. Brunetti3, Robert K. Stad3, Michele McDermott3, Brian D. Bradbury3 and Min Kim3, 1University of Alabama at Birmingham, Birmingham, AL, 2Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, 3Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than oral bisphosphonates, evidence is lacking…
  • Abstract Number: 2412 • ACR Convergence 2023

    Evaluation of the Pretest Probability Score, Ultrasound and Biopsy on GCA Diagnose: Data from Real Clinical Practice

    María del Carmen San José Méndez1, Uxía Couto Lareo1, Vanesa Balboa Barreiro2, Francisco J. Blanco1, Bruno de aspe de la iglesia1, Antonio Atanes Sandoval3, Diego Dios Santos1, Jesús Carlos Fernández López1, Mercedes Freire González1, Guillermo González Arribas1, Genaro Graña Gil1, Natividad Oreiro Villar1, Jose Antonio Pinto Tasende1, Francisco Javier De Toro Santos1, Clara Ventin Rodriguez1, Maite silva díaz3 and Ana Lois Iglesias1, 1Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 2Clinic epidemiology and biostatistics department. Complejo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 3Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain

    Background/Purpose: Giant cell arteritis (GCA) affects large and medium size arteries. Biopsy was considered the gold standard in the diagnosis1, but in the last years…
  • Abstract Number: 2485 • ACR Convergence 2023

    Comparative Risk of Serious Psychiatric Events with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus

    April Jorge1, Baijun Zhou1, Yuqing Zhang2 and Hyon K. Choi3, 1Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital and Harvard Medical School, Lexington, MA

    Background/Purpose: In randomized placebo-controlled trials, including the phase 4 Belimumab Assessment of Safety in SLE study, belimumab use was associated with a higher incidence of…
  • Abstract Number: 0155 • ACR Convergence 2023

    Cost Analysis of Subcutaneous Methotrexate Compared to Oral Methotrexate Treatment for Rheumatoid Arthritis

    Aniket Kawatkar, David Yi, Erika Estrada and Cecilia Portugal, Kaiser Permanente Southern California, Pasadena, CA

    Background/Purpose: Rheumatoid Arthritis (RA)patients who switch from oral to subcutaneous methotrexate (MTX) may experience better response to treatment due to increased bioavailability, enhanced tolerability, increased…
  • Abstract Number: 2529 • ACR Convergence 2023

    Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

    Jeffrey R Curtis1, Tarun Arora2, Ye Liu3, Vanessa C. Brunetti4, Tzu-Chieh Lin4, Leslie Spangler4, Robert K. Stad4, Michele McDermott4, Brian D. Bradbury4 and Min Kim4, 1Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 2Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from…
  • Abstract Number: 0199 • ACR Convergence 2023

    Experience in Real-World Conditions of the Effectiveness of the Vaccine Against Herpes Zoster Virus

    Laura Mas Sanchez1, Pablo Francisco Muñoz Martínez2, Elena Grau Garcia3, Alba Maria Torrat Noves3, Daniel Ramos Castro3, Carmen Riesco Barcena3, Anderson Victor Huaylla Quispe3, Belen Villanueva Mañez3, Iago Alcantara Alvarez3, Samuel Leal Rodriguez3, Marta De la Rubia Navarro1, Ernesto Tovar Sugrañes3, Jose Ivorra Cortes3, Luis Gonzalez Puig3, Rosa Negueroles Albuixech3, Elvira Vicens Bernabeu3, Jose Eloy Oller Rodriguez3, Isabel Martinez Cordellat3, Hikmat Charia3, Ines Canovas Olmos3, Carmen Najera Herranz3 and Jose Andres Roman Ivorra4, 1Rheumatology Department. HUP La Fe, Valéncia, Spain, 2Rheumatology Department. HUP La Fe, Sagunto, Spain, 3Rheumatology Department. HUP La Fe, Valencia, Spain, 4Hospital Universitari i Politècnic la Fe, Valencia, Spain

    Background/Purpose: Herpes zoster infection is due to the reactivation of the varicella-zoster virus (VZV), having a high prevalence in elderly and immunocompromised patients. Since the…
  • Abstract Number: 2542 • ACR Convergence 2023

    Impact of Concomitant Methotrexate on Disease Activity After Tapering Abatacept in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study

    Jun Won Park1, Min Jung Kim2, Hyoun-Ah Kim3, Jin Hyun Kim4 and Kichul Shin5, 1Seoul National University Hospital, Seoul, South Korea, 2Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, 3Ajou University School of Medicine, Suwon, South Korea, 4Chungnam National University College of Medicine, Daejeon, South Korea, 5Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea

    Background/Purpose: Recent randomized-controlled studies have suggested that tapering bDMARDs and/or csDMARDs after achieving sustained remission in patients with rheumatoid arthritis (RA) can be considered. However,…
  • Abstract Number: 0441 • ACR Convergence 2023

    Outcomes in Patients with Rheumatoid Arthritis Initiating Therapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors

    Dimitrios Pappas1, Jacqueline O’Brien1, Lin Guo1, Ying Shan1, Joshua Baker2, Gregory Kricorian3, Scott Stryker4 and David Collier3, 1CorEvitas, LLC, Waltham, MA, 2University of Pennsylvania, Philadelphia, PA, 3Amgen, Inc., Thousand Oaks, CA, 4Amgen, Inc., San Francisco, CA

    Background/Purpose: Ongoing debate exists regarding the optimal sequence of tumor necrosis factor inhibitors and Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA) as…
  • Abstract Number: 0606 • ACR Convergence 2023

    Risk of Damage Progression with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus

    April Jorge1, Baijun Zhou1, Yuqing Zhang2 and Hyon K. Choi3, 1Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital and Harvard Medical School, Lexington, MA

    Background/Purpose: Belimumab was approved for the treatment of non-renal SLE in 2011 and has been previously associated with a lower risk of damage progression when…
  • Abstract Number: 0786 • ACR Convergence 2023

    A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort

    Anna Arar, Diane L. Kamen, Paul Nietert and Melissa Cunningham, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Manifestations of systemic lupus erythematous (SLE) vary in severity and presentation; lupus nephritis (LN) affects up to half of SLE patients and confers a…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology